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Endosomal Localization Signal Required for Efficient
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Wehave identified and characterized aMicrotubule Interact-
ing and Transport (MIT) domain at the N terminus of the deu-
biquitinating enzymeUBPY/USP8. In commonwith otherMIT-
containing proteins such as AMSH and VPS4, UBPY can
interact with CHMP proteins, which are known to regulate
endosomal sorting of ubiquitinated receptors. Comparison of
binding preferences for the 11 members of the human CHMP
family between the UBPY MIT domain and another ubiquitin
isopeptidase, AMSH, reveals common interactions with
CHMP1A and CHMP1B but a distinct selectivity of AMSH for
CHMP3/VPS24, a core subunit of the ESCRT-III complex, and
UBPY for CHMP7. We also show that in common with AMSH,
UBPY deubiquitinating enzyme activity can be stimulated by
STAM but is unresponsive to its cognate CHMPs. The UBPY
MIT domain is dispensable for its catalytic activity but is essen-
tial for its localization to endosomes. This is functionally signif-
icant as an MIT-deleted UBPY mutant is unable to rescue its
binding partner STAM from proteasomal degradation or
reverse a block to epidermal growth factor receptor degradation
imposed by small interfering RNA-mediated depletion of
UBPY.
Lysosomal degradation rates determine the levels of cell sur-
face receptor tyrosine kinases, an important parameter in the
control of cell growth (1, 2). Activated receptors are internal-
ized and consequently committed to the lysosomal pathway by
budding from the limiting membrane of the early endosome
into lumenal vesicles, which define the multivesicular body
(MVB).3 Ubiquitination of receptors is required for their sort-
ing into MVBs, which precludes their recycling to the plasma
membrane (3, 4).
The constituents of the endosomal sorting machinery were
initially identified as class E mutants in screens for vacuolar
protein-sorting (VPS) defects in Saccharomyces cerevisiae (5,
6), characterized by an expanded pre-vacuolar compartment
(7). These engage in a complex set of protein-protein interac-
tions, which link four core complexes (endosomal sorting com-
plexes required for transport, ESCRTs-0, I, II and III), and
somehow impart directionality to the process (5, 8–11). It has
been proposed that ESCRT-0 (comprising Hrs (hepatocyte
growth factor-regulated tyrosine kinase substrate) and STAM
(signal-transducing adaptor molecule)) may provide the first
means of engagement with ubiquitinated receptor (12–15)
through ubiquitin interactionmotifs in both proteins, although
both ESCRT-I and -II also contain ubiquitin-binding proteins
(10, 16). In yeast, ESCRT-III is composed of four subunits
(VPS2/Chm2, VPS24/Chm3, Snf7/Chm4, VPS20/Chm6),
whereas mammals possess an expanded complement of iso-
forms, CHMP2A/B, CHMP3, CHMP4A/B/C, and CHMP6,
providing the possibility for distinct ESCRT-III functions
through combinatorial coding of core components. Two
related proteins, Did2/VPS46/Chm1 and VPS60/MOS10/Chm5
(CHMP1A/B and CHMP5 in mammals), have poorly defined
auxiliary roles in MVB sorting (17–19), and a further mamma-
lian CHMP protein (CHMP7) has no yeast orthologue (20). All
the CHMPs (charged MVB proteins) are characterized by a
polarized distribution of charge: the N terminus is highly basic
whereas the C terminus is highly acidic (17, 21).
Ubiquitination can be reversed by the action of deubiquiti-
nating enzymes (DUBs), of which there are 84 predicted active
members in the human genome (22, 23). Two mammalian
DUBs (UBPY (ubiquitin-specific protease Y) and AMSH (asso-
ciated molecule with the Src homology 3 domain of STAM))
compete for a common binding site on the Src homology 3
domain of the ESCRT-0 component STAM (24–26). Interest-
ingly, siRNA-mediated depletion of each of these twoDUBs has
opposite effects on epidermal growth factor (EGF) receptor
(EGFR) degradation; AMSH knock down promotes EGF and
EGFRdegradation (27, 28) whereasUBPY knock down is inhib-
itory (28–30). This effect of UBPY knock down is also in
accordance with recent overexpression studies (31).
The last resolvable step of theMVB sorting pathway involves
the AAA-ATPase VPS4 and may be coupled to disassembly of
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the ESCRTmachinery (32–34). Both AMSH and VPS4 interact
with ESCRT-III components through microtubule interacting
and transport (MIT) domains (35–37), first identified in
SNX15, spastin, and spartin (38). We have identified an MIT-
like domain in UBPY. In this study we define the specificity of
its CHMP protein interactions and show that it is necessary for
the recruitment of UBPY to endosomes as well as for effective
EGFR down-regulation.
EXPERIMENTAL PROCEDURES
Bioinformatics—All data base searches were performed as
previously described (39) using a non-redundant data set con-
structed fromcurrent releases of SwissProt, TrEMBL, andGen-
pept. Generalized profile construction and searches were run
locally using the pftools package. Profiles were constructed
using the BLOSUM45 substitution matrix. The statistical sig-
nificance of profilematcheswas derived from the analysis of the
score distribution of a randomized data base.
Plasmids—UBPY-(1–133), UBPY-(1–438), UBPY-His6, and
UBPY!MIT (lacking amino acids 1–123) were generated by
PCR using PfuUltraHF (Stratagene) and pGEMT-UBPY (29) as
a template (primer sequences available on request), sequenced,
and subcloned into a yeast two-hybrid bait vector (pFBT9, a
modified pGBT9), pGEX6P, and pEGFP-C1. AMSH bait and
CHMP prey constructs have been described previously (35).
The open reading frame of CHMP1B was PCR-amplified
using pDEST-CHMP1B as template, sequenced, and sub-
cloned into pET15b to generate an N-terminal His6 tag.
pET15b-VPS24 was a generous gift from Paul Whitley (40).
pCDNA3-myc-CHMPs, GFP-UBPY, GFP-UBPY(C786S),
siRNA-resistant GFP-UBPY*, GFP-AMSH, His6-STAM,His6-
STAM!SH3, His6-STAM!UIM (i.e. STAM(L175/L176A))
have been previously described (27, 29, 35). siRNA-resistant
GFP-UBPY*(C786S) was generated by inserting a BbvI-BamHI
fragment from GFP-UBPY* into GFP-UBPY(C786S) and GFP-
UBPY!MIT(C786S) by inserting an EcoRI-XmaI fragment
from GFP-UBPY(C786S) into GFP-UBPY!MIT. pGEXP-
UBPY(C786S)-His6was generated by subcloning an EcoRI-StuI
fragment from pEGFPC1-UBPY (C786S) into pGEX6P-
UBPY-His6. pGEX6P-UBPY!MIT-His6 was produced by
subcloning a BamHI-EcoRI fragment from pCMV-Tag2B-
UBPY-!MIT into pGEX6P-UBPY-His6.
Yeast Two-hybrid—All bait constructs were transformed
into the PJ69–4A MATa strain, while prey constructs were
expressed in the complementary mating type-switched strain
PJ69–4A MAT!. Targeted yeast two-hybrid matrix experi-
ments were performed as described previously (41). Selective
growth of diploid yeast was assessed on (–) His/plates contain-
ing 2.5 mM 3-AT, and screens were repeated to ensure that
growth phenotypes were reproducible. In each case, colony
growth was recorded after 5 days of incubation at 30 °C.
Antibodies and Other Reagents—Primary antibodies used
were as follows: mouse monoclonals anti-Myc (4A6) (Upstate),
anti-EGFR RI (CRUK) (UK), anti-His6 (Amersham Bio-
sciences), anti-tubulin (Sigma), anti-GFP (Roche Applied
Sciences), and polyclonal antibodies affinity-purified sheep
anti-GFP (gift from Ian Prior, University of Liverpool), rab-
bit anti-ubiquitin (Sigma), rabbit anti-CHMP1B (gift from
Evan Reid, University of Cambridge). Rabbit anti-Hrs and
anti-STAM have previously been described (42, 43). Second-
ary horseradish peroxidase-coupled antibodies, horseradish
peroxidase-coupled anti-GST, and Protein-G-agarose were
obtained from Sigma. Donkey IR700 and IR800-coupled
anti-mouse and anti-rabbit secondary antibodies were from
Rockland, and AF594-coupled donkey anti-mouse antibod-
ies were from Molecular Probes.
Protein Production—GST-UBPY-His6, GST-UBPY(C786S)-
His6, and GST-UBPY!MIT-His6 expression in Rosetta (DE3)
pLysS cells (Novagen) was induced with 0.4 mM isopropyl-1-
thio-"-D-galactopyranoside (0.4 mM) for 4 h at 20 °C. The bac-
teria were lysed by sonication, and the protein was purified first
with nickel-nitrilotriacetic acid-agarose (Qiagen) and thenwith
glutathione-Sepharose (Amersham Biosciences), both used
according to themanufacturer’s instructions and dialyzed against
50mMTris, pH 7.2, 25mMKCl, 5mMMgCl2, 1mMdithiothreitol.
GST-UBPY-(1–133), GST-UBPY-(1–438), GST-AMSH, His6-
CHMP1B, and His6-CHMP3 were expressed in Rosetta (DE3)
pLysS cells (Novagen) and purified with glutathione-Sepharose
(Amersham Biosciences) (GST-tagged) or nickel-nitrilotriacetic
acid-agarose (Qiagen) (His6-tagged) according to themanufac-
turer’s instructions.
Pulldown Experiments—Purified His6-CHMP1B or His6-
CHMP3 (22 pmol) was incubated with 110 pmol GST, GST-
UBPY-(1–133), GST-UBPY-(1–438), or GST-AMSH at 4 °C
for 1 h in 300 #l of assay buffer (20 mM Hepes, pH 7.3, 120 mM
KOAc, 0.1 mM dithiothreitol, 0.1% Triton X-100, and protease
inhibitors). After brief centrifugation, the supernatants were
incubatedwith 30#l of glutathione-Sepharose at room temper-
ature for 30 min. The beads were washed three times with
buffer WB (20 mM Hepes, pH 7.3, 120 mM KOAc, and 0.1 mM
dithiothreitol, 0.1% Triton X-100) and once with WB minus
Triton X-100 before elution in SDS-PAGE sample buffer. In
vitro translated Myc-CHMP proteins were produced with the
TNT!Quick-coupled Transcription/Translation system (Pro-
mega) according to the manufacturer’s instructions using
pCDNA3-myc-CHMP constructs. Purified GST, GST-UBPY-
(1–133), or GST-AMSH (220 pmol) were each incubated with
10 #l of in vitro translated product at 4 °C for 1 h in 300 #l of
assay buffer. After brief centrifugation, the supernatants were
incubatedwith 40#l of glutathione-Sepharose at room temper-
ature for 30 min and processed as above. Bound proteins were
eluted with SDS-PAGE sample buffer and analyzed in parallel
with a fraction of the input material by immunoblotting with
anti-Myc or anti-His6 antibodies, followed by IR800-coupled
secondary antibodies. TheWestern blotswere analyzed and the
results quantified using a LI-COR Odyssey 2.1. Samples were
reprobed with horseradish peroxidase-coupled anti-GST,
developed by enhanced chemiluminescence (Pierce), and sig-
nals captured with a Uvichemi Gel documentation system
(Uvitech) and quantified using Image J. The percentage of pull-
down was calculated relative to the input after subtraction of
the background signal attributable to GST alone.
Cell Culture, Transfection, and RNA Interference Ex-
periments—HEK293T andHeLa cells were cultured inDulbec-
co’s modified Eagle’s medium supplemented with 10% fetal
bovine serum and 1% non-essential amino acids, transfected
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with GeneJuice (Merck Biosciences), and lysed or fixed for
immunofluorescence 24 h post-transfection as previously
described (29). For siRNA experiments, HeLa cells were treated
twice over 96 h (24 and 72 h after the initial seeding) with either
Control siRNA duplex (Nonspecific Control VII) or UBPY-spe-
cific siRNAduplex 1 (senseUGAAAUACGUGACUGUUUAUU,
antisense 5"-PUAAACAGUCACGUAUUUCAUU; Dharmacon,
Lafayette, CO) at 40.8 nM concentration using Oligofectamine
(Invitrogen) in theabsenceof serum.Fetalbovine serum(10%)was
added4hpost-transfection.For rescueexperiments, thecellswere
transfected66hbeforeharvestingwithpEGFPC1, siRNA interfer-
ence-resistantGFP-UBPY(UBPY*),GFP-UBPY!MIT,or catalyt-
ically inactive GFP-UBPY*(C786S). Cells were serum-starved
for 16 h and stimulated with EGF (100 ng/ml) for 4 h to induce
internalization and degradation of EGFR. Cells were either
lysed and samples analyzed by Western blotting or fixed in
paraformaldehyde and processed for immunofluorescence
staining with anti-EGFR as described below. The percentage of
GFP-positive cells that retained EGFR after 4 h of EGF treat-
ment was determinedmanually by counting cells on an epifluo-
rescence microscope.
Immunofluorescence—Cells were processed for immunoflu-
orescence by fixation with 3% paraformaldehyde in PBS, per-
meabilization with 0.2% Triton X-100 in PBS, and preincuba-
tion in 10% goat serum in PBS. The cells were stained with
anti-EGFR followed by Alexa-Fluor 594-coupled secondary
antibodies, both diluted in 5% goat serum in PBS. Confocal
images were captured with a Leica confocal SP2 AOBS (HCX
PL APO CS 63.0# 1.40 oil objective).
Cell Lysis and Immunoprecipitation—Cells were washed
with ice-cold PBS and incubated for 10 min on ice in Nonidet
P-40 lysis buffer (1%Nonidet P-40, 25mMTris/HCl, pH7.5, 100
mM NaCl, 50 mM NaF). Lysates were cleared by centrifugation
and incubated with sheep anti-GFP and Protein-G-agarose for
FIGURE1.UBPYcontainsapredictedMITdomain.A, sequence alignmentof predictedMITdomainswithin thehumanand S. cerevisiaegenomes. Thehuman
genome contains 14 predicted MIT domains within 12 proteins while the yeast genome contains two MIT-containing proteins. Accession numbers (Uniprot)
are, respectively, SPAST: Q9UBP0; VPS4a: Q9UN37; VPS4b: O75351; AMSH: O95630; AMSHLP: Q96FJ0; UBPY: P40818; SPG20: Q8N0X7; SNX15: Q9NRS6;
RPS6KC1:Q5VUN8; RPS6KL1:Q9Y6S9; ULK3:Q8K1X6 (mouse); CAPN7:Q9Y6W3; LOC129531:Q8WV92; yeast (all SGD) VPS4: YPR173C; YLR073C: YLR073C. ULK3
andCAPN7each contain twopredictedMIT domains; in each case, themostN-terminalMIT is designated as “1” and thedownstreamMIT as “2”. B, dendrogram
of human and S. cerevisiae “MIT proteins” reveals the UBPYMIT domain to bemost closely related to that of two other DUBs, AMSH and AMSH-LP, as well as a
yeast protein (Ylr073) of unknown function lacking a DUB catalytic domain.
Function of the UBPYMIT Domain
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2 h at 4 °C. Beads were washed three times with YP-IP buffer
(0.1% Nonidet P-40, 25 mM Tris/HCl, pH 7.5, 150 mM NaCl),
once with 10 mM Tris/HCl, pH 7.5, and resuspended in 1.5#
SDS-PAGE sample buffer. Eluted proteins were resolved by
SDS-PAGE followed by immunoblotting.
DUB Assay—GST-UBPY-His6 (20 nM), preincubated with
His6-STAM or His6-CHMP proteins (200 nM) for 30 min at 4 °C,
was incubated with wild-type Lys-63-linked tetraubiquitin
chains (0.4#M; Boston Biochem) in 20#l of DUB buffer (50mM
Tris/HCl, 25mMKCl, 5mMMgCl2, 1mMdithiothreitol, pH7.2)
for 2 h at 37 °C. Proteins were resolved on 4–12%NuPAGE gels
(Invitrogen) and transferred to nitrocellulose. The membranes
were boiled for 30 min in deionized water, blocked in 5% Fish
Skin Gelatin, 0.1% Tween 20 in PBS, and probed with a rabbit
antibody to ubiquitin (Sigma) and processed with secondary
antibodies as described above.
RESULTS
UBPY Contains an MIT Domain—Fig. 1A shows an align-
ment of the N-terminal region of UBPY with VPS4 and other
MITdomain-containing proteins, suggesting that like the other
STAM binding DUB, AMSH, UBPY also contains an MIT
domain. We have identified 14 predicted MIT domains within
12 proteins in the human genome. This represents a large
expansion from the S. cerevisiae genome, which contains only
VPS4 and Ylr073c, a protein of unknown function. The associ-
ated dendrogram shows that among MIT domain-containing
proteins in the human genome, the UBPY-MIT most closely
resembles AMSH and a related protein, AMSH-LP (Fig. 1B).
UBPY and AMSH Show Overlapping but Distinct CHMP
Binding Profiles—We and others (35, 36, 44) have previously
shown that AMSH interacts with multiple CHMP proteins and
that the MIT domain is responsible for its interaction with the
ESCRT-III component VPS24/CHMP3.We tested interactions
of the UBPY MIT domain with ten human CHMP proteins
using a directed yeast two-hybrid screen.When expressed from
a bait construct, the N terminus of UBPY (residues 1–133)
incorporating theMIT domain shows a strong interaction with
CHMP1B but a greatly restricted CHMP interaction profile
compared with AMSH (Fig. 2). Note that under these assay
conditions CHMP6 was found to auto-activate the yeast two-
hybrid (His) reporter. No interactions were seen when the
UBPY MIT domain was expressed from a prey construct (not
shown). This selectivity indicated by the two-hybrid screen was
retained in a direct binding assay between proteins purified
from bacteria. We tested the interaction of GST-AMSH and
GST-UBPY-(1–133) or a longer fragment GST-UBPY-(1–438)
(Fig. 2A) with His6-tagged CHMP1B and CHMP3 (Fig. 3). The
UBPY MIT domain directly interacts with CHMP1B but not
with CHMP3, whereas AMSH interacts with both CHMPs as
indicated in the yeast two-hybrid assay.
We next directly compared the CHMP binding profile of
bacterially expressed GST-UBPY-(1–133) and GST-AMSH
toward the complete panel of 11 human Myc-tagged CHMP
proteins, which were produced by in vitro translation. In this
configuration, the UBPYMIT domain-(1–133) as well as a lon-
ger fragment (1–438, not shown) shows clear interactions with
CHMP1A, 1B, 4C, and 7. This contrasts clearlywith the binding
profile for GST-AMSH, which does not bind CHMP7 but
shows clear binding to CHMP3 (Fig. 4).
Finally, we confirmed the specific interaction of full-length
UBPYwith CHMPs 1A and 1B in cells by immunoprecipitation
of GFP-UBPY fromHEK293T cells co-expressing variousMyc-
tagged CHMP proteins. Also in the context of the full-length
protein, selective binding was observed with CHMP1A,
CHMP1B, and CHMP7 (not shown) but not with CHMP3 (Fig.
5A). Low level binding to CHMP5 is most likely indirect as
CHMP5 interacts with CHMP1B in a yeast two-hybrid assay (9,
FIGURE 2.CHMP interaction profile of AMSHandUBPY-(1–133) in a yeast
two-hybrid assay. A, schematic diagram of the domain structure of UBPY
and the constructs used in this study. RHOD, Rhodanese domain. B, profiles
for yeast two-hybrid interactionsobservedwhen strains expressingeither the
UBPY-(1–133) fragment or full-length AMSH were mated against strains
expressing a collection of human CHMP proteins (1A, 1B, 2A, 2B, 3, 4A, 4B, 4C,
5, and 6). Shaded gray boxes reflect relative colony growth on (–) His plates
containing 2.5 mM 3-AT at 5 days post-replication. Gal4BD- and Gal4AD- indi-
cate “bait” and “prey” constructs, respectively. A indicates auto activation/
nonspecific promiscuous growth.
FIGURE 3. Validation of direct CHMP1B-UBPY interaction using bacteri-
ally expressed proteins. Purified GST, GST-UBPY-(1–133), GST-UBPY-(1–
438), or GST-AMSH (110 pmol each) were co-incubated with His6-CHMP1B
andHis6-CHMP3 (22pmol each) for 1 hon ice as describedunder “Experimen-
tal Procedures.” Proteins were isolated with glutathione-Sepharose beads
and analyzed in parallel with a sample of the input material (23% His6-
CHMP1B and 36% His6-CHMP3) by immunoblotting with anti-His6 and anti-
GST. These data recapitulate results obtained in the two-hybrid assay (Fig. 2)
whereinbothAMSHandUBPY interactwithCHMP1BbutonlyAMSH interacts
directly with CHMP3.
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35) and does not showup as aUBPYbinding partner in either of
the other assays. Importantly, the MIT domain is clearly nec-
essary for UBPY binding to CHMP1B as a GFP-UBPY!MIT
construct no longer co-immunoprecipitates with CHMP1B
(Fig. 5B).
STAM, butNot CHMP, Interaction
Stimulates UBPY DUB Activity—
We have previously shown that the
AMSH- andUBPY-interacting part-
ner STAM can stimulate AMSH
DUB activity in an in vitro assay in a
manner dependent on the ubiquitin
interaction motif domain of STAM
(44). We now show that STAM can
also stimulate UBPY DUB activity
on enzymatically produced wild-
type Lys63- and Lys48-linked tet-
raubiquitin chains in the same in
vitro assay format (Fig. 6A and data
not shown). In contrast, incubation
with the newly identified UBPY-in-
teracting partner CHMP1B had no
effect on UBPY DUB activity either
on its own or in combination with
STAM, mirroring the failure of the
AMSH binding partner CHMP3 to
stimulate AMSH activity (Fig. 6A)
(44). Removal of the MIT domain
does not compromise the activity of
UBPY in this in vitro setting or its
ability to be stimulated by STAM
(Fig. 6B).
The MIT Domain Is Required for
Endosomal Localization of UBPY—
GFP-UBPY is largely cytosolic in
serum-starved cells but partially
redistributes to early endosomes
containing EGFR upon acute EGF
stimulation (29, 45). No corre-
sponding redistribution is observed
with GFP-UBPY!MIT despite the
retention of two STAM binding
sites in this protein, suggesting
these are not sufficient for endoso-
mal localization (Fig. 7, A–F). A
catalytically inactive mutant of
UBPY, GFP-UBPY(C786S), con-
stitutively associates with endo-
somes that accumulate ubiquitin
(29). Both endosomal localization
(Fig. 7, G–L) and accumulation of
ubiquitin on endosomes (not
shown) are lost following deletion
of the MIT domain from this
mutant (GFP-UBPY!MIT(C786S)).
The MIT Domain of UBPY Is
Required for Maintenance of
ESCRT-0 Stability and EGFR
Degradation—A characteristic of UBPY-depleted cells is that
STAM is no longer protected from proteasomal degradation by
UBPY-mediated de-ubiquitination (29), resulting in the desta-
bilization of both ESCRT-0 components, Hrs and STAM.
Expression of siRNA-resistant GFP-UBPY* partially recovers
FIGURE 4. Interaction profile of GST-AMSH and GST-UBPY-(1–133) with in vitro translated (IVT) Myc-
tagged CHMP proteins. A, purified GST, GST-UBPY(1–133), or GST-AMSH (220 pmol) were incubated with in
vitro translatedMyc-CHMPs (1A,1B,2A,2B,3,4A,4B,4C,5,6, and7) at 4 °C for 1h. Theproteinswere isolatedwith
glutathione-Sepharose beads and analyzed in parallel with a sample (20%) of the in vitro translated input by
immunoblottingwith anti-Myc and anti-GST (a representative blot is shown for the latter in the bottom panel).
B, quantification of the results shown in panel A. The efficiency of the pull downwas assessed as percentage of
the input bound to GST-UBPY-(1–133) and GST-AMSH after subtraction of the background signal (fraction
bound to GST alone). The percentage bound to either UBPY or AMSH was then normalized to the strongest
binder, CHMP1A, to allow direct comparison of the selectivity within the binding profiles. Note that UBPY and
AMSH show both common (CHMP1A, CHMP1B, CHMP4C) and clearly distinct binding partners (CHMP3 and
CHMP7).
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Hrs and STAM levels, whereas GFP-UBPY!MIT or catalyti-
cally inactive GFP-UBPY*(C786S) are ineffective (Fig. 8) in this
context. No significant changes in levels of the UBPY binding
partner CHMP1B were observed following UBPY knock down
and overexpression (Fig. 8).
Knock down of endogenous UBPY also leads to a failure to
degrade EGF and EGFR (28–30). Prolonged EGF stimulation
results in the loss of receptor from control cells as judged by
immunofluorescence, but in UBPY-depleted cells the receptor is
retained inclusteredendosomal structures (29).Wehaveused this
assay to investigate the role of the MIT domain with respect to
UBPY function. Expression of siRNA-resistant GFP-UBPY* in
UBPY knockdown cells efficiently rescues this degradation defect,
whereas neitherGFP-UBPY!MITorGFP-UBPY*(C786S) can do
so (Fig. 9). Overexpression of GFP-UBPY!MIT in untreated or
control siRNA-treated cells did not interfere with receptor down-
regulation, suggesting that it does not act as a dominant negative
mutant in this context.
DISCUSSION
The human genome encodes 14 predicted MIT domains
within 12 proteins, of which several have previously been
shown to interact with CHMPproteins. Some of these are quite
promiscuous, such as AMSH (35, 36) or VPS4 (9, 11, 35),
whereas others such as AMSH-LP have no apparent binding
partners (35, 36). Although not so far confirmed through rigor-
ous systematic analysis, available data suggest some specificity
of spastin for CHMP1B (46) and of MITD1 for CHMP2A (35).
Having identified UBPY as an MIT domain protein through
sequence alignment, we could confirm the presence of an MIT
domain signature of three !-helices by examination of a
recently published study that provides a crystal structure for the
N terminus of UBPY (47). The structure of the UBPY MIT
domain is highly similar to that determined for VPS4 (37).
The MIT domain proteins AMSH, UBPY, and VPS4 all
influence endosomal sorting and bind to CHMP proteins. It
is important therefore to define the respective CHMP bind-
FIGURE 5. Co-immunoprecipitation of full-length GFP-UBPY with
CHMP1BfromHEK293Tcells.A, GFP-UBPYorGFP-AMSHwereco-expressed
with various Myc-tagged CHMP proteins in HEK293T cells and immunopre-
cipitated with anti-GFP prior to blotting with anti-GFP and anti-Myc antibod-
ies. As indicated in preceding assays both proteins interactwith CHMP1A and
CHMP1B, whereas only AMSH interacts with CHMP3. The interaction with
CHMP5 seen in this assay may be indirect (see “Results”). B, co-immunopre-
cipitation between CHMP1B and UBPY is lost upon deletion of the MIT
domain. Myc-CHMP1B and GFP-UBPY, GFP-UBPY!MIT, or GFP-UBPY(C786S)
were co-expressed in HEK293T cells and processed as described above.
FIGURE 6. A, STAM, but not CHMP, interaction stimulates UBPY DUB activity.
Full-lengthbacterially expressedandpurifiedGST-UBPY-His6 (20nM)waspre-
incubated for 30 min on ice with purified His6-STAM, His6-CHMP1B, or His6-
CHMP3 (all 200 nM) prior to incubation with Lys-63-linked tetraubiquitin
chains (0.4 #M) for 2 h at 37 °C. The samples were analyzed by SDS-PAGE
followed by immunoblotting with anti-ubiquitin (top panel) and anti-His6
antibodies (bottom panel). B, the MIT domain is dispensable for UBPY DUB
activity in vitro. Bacterially expressed and purified GST-UBPY-His6, GST-
UBPY(C786S)-His6, orGST-UBPY!MIT-His6 (all at 24nM)werepreincubated for
30 min on ice with purified His6-STAM (240 nM) and then incubated with
Lys-63-linked tetraubiquitin chains (0.4#M) for 2 h at 37 °C. The sampleswere
analyzed by SDS-PAGE followed by immunoblotting with anti-ubiquitin (top
panel) and anti-His6 antibodies (bottom panel).
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ing profiles of each MIT domain. Our two-hybrid analysis
indicated common binding of AMSH and UBPY to CHMP1B
(also shared by VPS4) but in addition a specific preference of
AMSH for other CHMPs, including CHMP3. In fact, the
AMSH MIT domain is the only one so far characterized to
display CHMP3 binding activity. In contrast to CHMP1B,
CHMP3 is a core component of the ESCRT-III complex that
is thought to act at a late stage in the sorting of membrane
FIGURE 7. Recruitment of UBPY to endosomes is contingent on an intact
MIT domain.HeLa cells transfected with GFP-UBPY, GFP-UBPY!MIT, or GFP-
UBPY(C786S) were serum-starved for 16 h before stimulation with EGF (100
ng/ml) for 10 min at 37 °C. The cells were fixed, permeabilized, and stained
with anti-EGFR followedbyAlexaFluor 594-labeled secondary antibodies and
analyzed by confocal microscopy 24 h post-transfection. GFP-UBPY translo-
cates from the cytosol to EGFR-containing endosomes in response to EGF
(panels A–C and Ref. 29). This redistribution is not seenwhen theMIT domain
is deleted (GFP-UBPY!MIT) (D–F). The catalytically inactive mutant GFP-
UBPY(C786S) constitutively associates with endosomes (G–I), but again this
localization is lost by removal of the MIT domain (GFP-UBPY!MIT(C786S))
(J–L). Insets showa 3-fold enlargement of the selected area. Scale bars, 10#m.
FIGURE 8. The MIT domain of UBPY is required for stabilization of ESCRT-0
components.HeLa cells were treatedwithUBPY siRNAor control siRNAprior to
transfection with GFP or GFP-tagged constructs expressing siRNA-resistant
UBPY*, UBPY!MIT, and UBPY*(C786S). Note that the UBPY-specific siRNA targets a
regioncorresponding to theMITdomain.Cellswere lysed, andsamplesanalyzedby
SDS-PAGEand immunoblottingwithHrs, STAM,CHMP1B, and tubulinantibodies.
FIGURE 9. The MIT domain of UBPY is required for regulation of EGFR
degradation.HeLa cells were treatedwith UBPY siRNA (A–I) or control siRNA
(J–L) and subsequently transfected with GFP-tagged constructs expressing
siRNA-resistant forms of UBPY andmutants thereof: UBPY* (A–C), UBPY!MIT
(D–F and J–L), and UBPY*(C786S) (G–I). Cells were serum-starved overnight
and stimulated for 4 h with EGF, which promotes the internalization and
degradation of EGFR in control cells but results in retention of EGFR in clus-
teredendosomes inUBPY-depletedcells. Cellswere fixed, permeabilized, and
stained with anti-EGFR followed by AlexaFluor 594-labeled secondary anti-
bodies and analyzed by confocal microscopy. Expression of GFP-UBPY*
restores EGFRdegradation in cells treatedwithUBPY-specific siRNA (A–C), but
this is not the case for UBPY!MIT (D–F) or the catalytically inactive form
UBPY*(C786S) (G–I). Overexpression of GFP-UBPY!MIT in control cells does
not interfere with EGFR degradation (J–L). Scale bars, 15 #m. The degree of
rescuewas assessedby counting thenumber of GFP-positive cells (outlined in
white) that retained EGFR for each of the constructs in a representative exper-
iment. Number of cells counted: GFP, 780; GFP-UBPY*, 754; GFP-UBPY!MIT,
338; GFP-UBPY*(C786S), 46.
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proteins into multivesicular bodies, although the molecular
details of the mode of action of these proteins are still
unclear.
A more comprehensive, quantitative, and direct analysis of
binding of all Myc-tagged CHMP proteins to GST-AMSH and
GST-UBPY-(1–133), while broadly in line with the two-hybrid
data, revealed further common binding partners in CHMP1A
and CHMP4C. Remarkably, UBPY showed a high degree of
specificity (compared with AMSH) for CHMP7. This recently
characterizedmember of the CHMP family inhibits EGFR deg-
radation on overexpression (20) but has hitherto not been
included in any of the screens for CHMP binding to MIT
domains.
The emerging picture is one of overlapping but distinct bind-
ing profiles of MIT domain proteins. Thus, some of these pro-
teins may compete with each other for the same binding sites
within the ESCRT machinery, while others will be more selec-
tive. The role of such specific interaction profiles is currently
unclear, as we still know too little about the functional contin-
gencies and redundancies within the family of CHMP proteins.
Thismay, however, ensure that association of eachMITprotein
with particular endosomes is governed by theCHMP repertoire
at that location.
Our observation that the UBPY MIT domain is essential for
endosomal localization is surprising, given that UBPY!MIT
retains at least two binding sites for the endosomal protein
STAM (24). For AMSH, endosomal localization is maintained
upon deletion of either the STAM binding site (44) or the MIT
domain (48), although deletion of both has not been tested.
Nevertheless, STAM stimulates UBPY activity as previously
observed for AMSH (44). We propose a model in which the
primary endosomal localization signal for UBPY involvesMIT-
CHMP interactions while the STAM interaction primarily
serves to present ubiquitinated substrates captured by STAM.
Interestingly, while both UBPY and STAM are also present in
cytosolic pools, the MIT domain, and by extension CHMP
binding, is required to protect STAM from proteasomal degra-
dation. This may suggest that in the cellular context CHMP
binding is important to direct UBPY activity toward specific
endosomal substrates.
Does endosomal localization of UBPY matter? UBPY knock
down has global effects on cellular protein ubiquitination pat-
terns (29, 49). However, we now show that its role in EGFR
trafficking requires endosomal localization through its MIT
domain. Rescue of an inhibitory effect on EGFR degradation
in UBPY-depleted cells requires both catalytic activity and
an intact MIT domain. In this respect, there are striking
parallels with the S. cerevisiae endosomal DUB, Doa4, which
requires endosomal association through its N-terminal
domain to undertake de-ubiquitination of protein cargo at
the MVB (50, 51).
In conclusion, we have demonstrated the importance of the
N terminus of UBPY encompassing the MIT domain for both
endosomal localization and physiological function. Endosomal
localization of UBPY is itself under the control of cell signaling
events, and it will be important to understand how this interac-
tion is regulated.
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TheMIT domain of UBPY constitutes a CHMP binding and endosomal localization signal required for efficient
epidermal growth factor receptor degradation.
Paula E. Row, Han Liu, SebastianHayes, RebeccaWelchman, Panagoula Charalabous, KayHofmann,Michael J. Clague, ChristopherM. Sanderson, and Sylvie Urbe´
Onpage 30933, note that the original Fig. 4 suggested a specific interactionbetweenCHMP7andUBPY,whichwas basedon experiments performedwith
amisidentified construct, resulting fromanerror in clonedistributionbetween labs.Wehave since repeated the experimentswith twonew independently
clonedCHMP7 constructs and didnot find any interaction betweenCHMP7 andUBPY.We sincerely apologize for any confusion that thismay have caused.
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